Meeting
2024 ASCO Breakthrough
Outcomes of EGFR, ALK, ROS1, BRAF, MET, and RET mutated non-small cell lung cancer with brain metastases (NSCLC BM).
Authors
Xiaoyan Li
Beijing Tian Tan Hospital, Capital Medical University, Beijing, Fengtai District, China
Xiaoyan Li , Weiwei Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Thoracic Cancers,Breast Cancer,Gynecologic Cancer,Head and Neck Cancer,Hematologic Malignancies,Genetics/Genomics/Multiomics,Healthtech Innovations,Models of Care and Care Delivery,Viral-Mediated Malignancies,Other Malignancies or Topics
Sub Track
Advanced Disease
Citation
J Clin Oncol 42, 2024 (suppl 23; abstr 201)
DOI
10.1200/JCO.2024.42.23_suppl.201
Abstract #
201
Poster Bd #
J6
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A nation-wide genomic screening project for further development of targeted therapies in treatment-refractory non–small-cell lung cancer (LC-SCRUM-TRY).
First Author: Hiroki Izumi
Poster
2020 ASCO Virtual Scientific Program
Biomarker utilization in non-small cell lung cancer, are we treating after testing?
First Author: Elias Makhoul
Poster
2018 ASCO Annual Meeting
Effects of comprehensive genomic testing in a large non-small cell cancer NSCLC cohort: Racial and survival impacts.
First Author: Fatemeh Ardeshir-Larijani
Poster
2014 ASCO Annual Meeting
Implementation of clinical next-generation sequencing (NGS) of non-small cell lung cancer (NSCLC) to identify EGFR amplification as a potentially targetable oncogenic alteration.
First Author: Geoffrey R. Oxnard